These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 38417790)
21. Disease-induced changes in the plasma binding of basic drugs. Piafsky KM Clin Pharmacokinet; 1980; 5(3):246-62. PubMed ID: 6156048 [TBL] [Abstract][Full Text] [Related]
22. Prediction of unbound propofol concentrations in a diabetic population. de la Fuente L; Lukas JC; Jauregizar N; Vázquez JA; Calvo R; Suárez E Ther Drug Monit; 2002 Dec; 24(6):689-95. PubMed ID: 12451283 [TBL] [Abstract][Full Text] [Related]
23. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Zhou HH; Adedoyin A; Wilkinson GR Clin Pharmacol Ther; 1990 Jul; 48(1):10-7. PubMed ID: 2369804 [TBL] [Abstract][Full Text] [Related]
24. Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay. Kosugi Y; Hosea N Mol Pharm; 2020 Jul; 17(7):2299-2309. PubMed ID: 32478525 [TBL] [Abstract][Full Text] [Related]
25. Comparison between lab variability and Fagerholm U; Spjuth O; Hellberg S Xenobiotica; 2021 Oct; 51(10):1095-1100. PubMed ID: 34346291 [TBL] [Abstract][Full Text] [Related]
26. Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. Christensen H; Baker M; Tucker GT; Rostami-Hodjegan A J Pharm Sci; 2006 Dec; 95(12):2778-87. PubMed ID: 16937340 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs. Hallifax D; Houston JB J Pharm Sci; 2012 Aug; 101(8):2645-52. PubMed ID: 22700322 [TBL] [Abstract][Full Text] [Related]
28. Implications of Incorporating Plasma Lipoprotein Binding into a Physiologically-Based Pharmacokinetic Model: A Simulation Study with Amiodarone. Doki K; Hashimoto N; Yoshida K; Homma M Clin Pharmacol Ther; 2024 May; 115(5):1015-1024. PubMed ID: 38093601 [TBL] [Abstract][Full Text] [Related]
30. Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach. Mayumi K; Ohnishi S; Hasegawa H J Pharm Sci; 2019 Aug; 108(8):2718-2727. PubMed ID: 30876861 [TBL] [Abstract][Full Text] [Related]
31. Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: emphasis on an apparent fraction unbound in liver for drugs. Poulin P J Pharm Sci; 2013 Jul; 102(7):2085-95. PubMed ID: 23613473 [TBL] [Abstract][Full Text] [Related]
32. A Novel Experimental and Theoretical Method for Estimating Albumin-Mediated Hepatic Uptake Based on the Albumin Binding Fraction in Plasma and Human PK Prediction Using a Physiologically-Based Pharmacokinetic Approach. Egashira Y; Shimada T; Mayumi K J Pharm Sci; 2021 May; 110(5):2262-2273. PubMed ID: 33476657 [TBL] [Abstract][Full Text] [Related]
33. Use of unbound volumes of drug distribution in pharmacokinetic calculations. Stepensky D Eur J Pharm Sci; 2011 Jan; 42(1-2):91-8. PubMed ID: 21050885 [TBL] [Abstract][Full Text] [Related]
34. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach. Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652 [TBL] [Abstract][Full Text] [Related]
35. Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. Imbs DC; Paludetto MN; Négrier S; Powell H; Lafont T; White-Koning M; Chatelut E; Thomas F Invest New Drugs; 2016 Feb; 34(1):41-8. PubMed ID: 26572909 [TBL] [Abstract][Full Text] [Related]
36. Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors? Guo C; Yang K; Liao M; Xia CQ; Brouwer KR; Brouwer KLR J Pharm Sci; 2017 Sep; 106(9):2401-2406. PubMed ID: 28465154 [TBL] [Abstract][Full Text] [Related]
37. Protein binding in antiretroviral therapies. Boffito M; Back DJ; Blaschke TF; Rowland M; Bertz RJ; Gerber JG; Miller V AIDS Res Hum Retroviruses; 2003 Sep; 19(9):825-35. PubMed ID: 14585213 [TBL] [Abstract][Full Text] [Related]